Joseph Hagan Biography and Net Worth

Mr. Hagan joined Regulus in January 2016 as Chief Operating Officer, Principal Financial Officer and Principal Accounting Officer and was appointed to President and Chief Executive Officer in May 2017. Mr. Hagan’s career includes roles as the Executive Vice President, Chief Financial Officer and Chief Business Officer of Orexigen Therapeutics, Inc., Managing Director of Amgen Ventures and head of corporate development for Amgen Inc. Mr. Hagan has led numerous strategic and financing transactions including the acquisitions of Immunex and Tularik and the spinout of Novantrone and Relyspa, as well as many other business development efforts totaling over $15 billion in value. Before joining Amgen, Mr. Hagan spent five years in the bioengineering labs at Genzyme and Advanced Tissue Sciences. Mr. Hagan currently serves on the board of directors of Zosano Pharma, a publicly traded biotechnology company. He received an M.B.A. from Northeastern University and a B.S. in Physiology and Neuroscience from the University of California, San Diego

What is Joseph P. Hagan's net worth?: The estimated net worth of Joseph P. Hagan is at least $358,611.00 as of January 30th, 2025. Mr. Hagan owns 260,808 shares of Regulus Therapeutics stock worth more than $358,611 as of March 6th. This net worth approximation does not reflect any other assets that Mr. Hagan may own. Additionally, Mr. Hagan receives an annual salary of $958,230.00 as CEO at Regulus Therapeutics. Learn More about Joseph P. Hagan's net worth.
How old is Joseph P. Hagan?: Mr. Hagan is currently 55 years old. There are 3 older executives and no younger executives at Regulus Therapeutics. Learn More on Joseph P. Hagan's age.
What is Joseph P. Hagan's salary?: As the CEO of Regulus Therapeutics Inc., Mr. Hagan earns $958,230.00 per year. Learn More on Joseph P. Hagan's salary.
How do I contact Joseph P. Hagan?: The corporate mailing address for Mr. Hagan and other Regulus Therapeutics executives is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. Regulus Therapeutics can also be reached via phone at (858) 202-6300 and via email at ccalsada@regulusrx.com. Learn More on Joseph P. Hagan's contact information.
Has Joseph P. Hagan been buying or selling shares of Regulus Therapeutics?: During the last ninety days, Joseph P. Hagan has bought $54,500.00 in shares of Regulus Therapeutics stock and sold $145,265.40 in shares of Regulus Therapeutics stock. Most recently, on Thursday, January 30th, Joseph P. Hagan bought 50,000 shares of Regulus Therapeutics stock. The stock was acquired at an average cost of $1.09 per share, with a total value of $54,500.00. Following the completion of the transaction, the chief executive officer now directly owns 260,808 shares of the company's stock, valued at $284,280.72. Learn More on Joseph P. Hagan's trading history.
Who are Regulus Therapeutics' active insiders?: Regulus Therapeutics' insider roster includes Christopher Aker (VP), Denis Drygin (Insider), and Joseph Hagan (CEO). Learn More on Regulus Therapeutics' active insiders.
Are insiders buying or selling shares of Regulus Therapeutics?: During the last twelve months, Regulus Therapeutics insiders bought shares 3 times. They purchased a total of 73,610 shares worth more than $82,566.60. During the last twelve months, insiders at the biopharmaceutical company sold shares 4 times. They sold a total of 223,998 shares worth more than $282,237.48. The most recent insider tranaction occured on January, 30th when CEO Joseph P Hagan bought 50,000 shares worth more than $54,500.00. Insiders at Regulus Therapeutics own 4.4% of the company. Learn More about insider trades at Regulus Therapeutics.
Information on this page was last updated on 1/30/2025.

Joseph P. Hagan Insider Trading History at Regulus Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/30/2025	Buy	50,000	$1.09	$54,500.00	260,808
1/13/2025	Sell	115,290	$1.26	$145,265.40	222,572
1/18/2024	Sell	14,580	$1.19	$17,350.20	57,112
1/26/2022	Buy	100,000	$0.22	$22,000.00
5/17/2021	Sell	4,186	$0.89	$3,725.54	316,292
2/16/2021	Sell	4,144	$1.72	$7,127.68	485,756
8/14/2020	Sell	4,245	$0.60	$2,547.00	222,088
5/15/2020	Sell	4,426	$0.63	$2,788.38	226,333
2/18/2020	Sell	4,324	$0.83	$3,588.92	230,759
1/2/2020	Sell	8,345	$0.97	$8,094.65	235,083
11/14/2019	Sell	5,838	$0.64	$3,736.32	243,428
10/1/2019	Sell	8,743	$0.68	$5,945.24	249,266
8/15/2019	Sell	4,375	$0.55	$2,406.25
7/1/2019	Sell	5,783	$1.31	$7,575.73	262,384
5/16/2019	Sell	39,352	$1.22	$48,009.44	307,519
5/7/2019	Buy	33,194	$1.08	$35,849.52	64,542
4/1/2019	Sell	5,842	$0.98	$5,725.16	31,348
7/25/2017	Buy	219,780	$0.91	$199,999.80	241,297
3/3/2016	Buy	10,000	$7.19	$71,900.00	10,000

Joseph P. Hagan Buying and Selling Activity at Regulus Therapeutics

Regulus Therapeutics Company Overview

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Today's Range

Now: $1.38

$1.31

$1.41

50 Day Range

MA: $1.31

$0.97

$1.61

2 Week Range

Now: $1.38

$0.83

$3.79

Volume

130,968 shs

Average Volume

526,639 shs

Market Capitalization

$90.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58

Joseph Hagan Biography and Net Worth

What is Joseph P. Hagan's net worth?

How old is Joseph P. Hagan?

What is Joseph P. Hagan's salary?

How do I contact Joseph P. Hagan?

Has Joseph P. Hagan been buying or selling shares of Regulus Therapeutics?

Who are Regulus Therapeutics' active insiders?

Are insiders buying or selling shares of Regulus Therapeutics?